A story published on the NY Times' front page directly undercuts comments made by NIH Director Francis Collins two weeks ago, but the story never mentions Collins or his misleading statement.
The NY Times story, which appears on AI today, is titled "Ebola Vaccine, Ready for Test, Sat on the Shelf." The story outlines two reasons why promising Ebola vaccines were still waiting for human trials:
Its development stalled in part because Ebola is rare, and until now,
outbreaks had infected only a few hundred people at a time. But experts
also acknowledge that the absence of follow-up on such a promising
candidate reflects a broader failure to produce medicines and vaccines
for diseases that afflict poor countries. Most drug companies have
resisted spending the enormous sums needed to develop products useful
mostly to countries with little ability to pay.